Chih-Kuo Lee1, Tzung-Dau Wang2, Ying-Hsiang Lee3,4, Martin Fahy5, Cheng-Han Lee6, Shih-Hsien Sung7, Hsien-Li Kao2, Yen-Wen Wu8, Tsung-Hsien Lin9. 1. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu. 2. Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei. 3. Cardiovascular Center, MacKay Memorial Hospital, Taipei. 4. Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. 5. Medtronic PLC, Santa Rosa, CA, USA. 6. Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, Tainan. 7. Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei. 8. Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City. 9. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital and Department of Internal Medicine, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract
BACKGROUND: It is unclear whether renal denervation (RDN) can safely result in blood pressure (BP) reductions in Asian hypertensive patients and whether such reductions would be sustainable. The study is to assess the safety and efficacy of RDN achieved by either main renal artery ablation using the Symplicity FlexTM catheter or main plus branch renal artery ablations using the Symplicity SpyralTM catheter in Taiwanese uncontrolled hypertensive patients enrolled in the Global SYMPLICITY Registry (GSR) with 3 years of follow-up. METHODS: The GSR is a prospective, open-label, and all-comer registry to evaluate the safety and effectiveness of RDN in patients with uncontrolled hypertension worldwide. RESULTS: Among 26 patients enrolled (mean age, 59.1 ± 13.8 years), 8 were treated with the Symplicity FlexTM catheter, and 18 were treated with the Symplicity SpyralTM catheter. Baseline office systolic BP was 168.2 ± 19.8 mmHg and diastolic BP was 89.0 ± 14.3 mmHg. Office BP reductions following RDN were sustained throughout the follow-up periods of up to 3 years in the Symplicity FlexTM group and 2 years in the Symplicity SpyralTM group. In the Symplicity FlexTM group, the office systolic BP reductions were 14.9 ± 14.7 mmHg and 29.7 ± 25.9 mmHg at 3 months and 3 years, respectively (both p < 0.05 from baseline). In the Symplicity SpyralTM group, the office systolic BP reductions were 21.2 ± 28.7 mmHg and 42.4 ± 10.7 mmHg at 3 months and 2 years, respectively (both p < 0.05 from baseline). There were no significant changes in heart rate or antihypertensive medication classes. Three protocol-defined adverse events occurred in 2 patients, including new-onset end-stage renal disease, stroke, and hospitalization for new-onset heart failure. CONCLUSIONS: Given the susceptibility of Asian populations to hypertension, RDN, as a safe antihypertensive procedure with long-lasting BP-lowering effects, could reliably serve as an alternative or complementary BP-lowering strategy for patients with uncontrolled hypertension in Taiwan and other Asian countries.
BACKGROUND: It is unclear whether renal denervation (RDN) can safely result in blood pressure (BP) reductions in Asian hypertensive patients and whether such reductions would be sustainable. The study is to assess the safety and efficacy of RDN achieved by either main renal artery ablation using the Symplicity FlexTM catheter or main plus branch renal artery ablations using the Symplicity SpyralTM catheter in Taiwanese uncontrolled hypertensive patients enrolled in the Global SYMPLICITY Registry (GSR) with 3 years of follow-up. METHODS: The GSR is a prospective, open-label, and all-comer registry to evaluate the safety and effectiveness of RDN in patients with uncontrolled hypertension worldwide. RESULTS: Among 26 patients enrolled (mean age, 59.1 ± 13.8 years), 8 were treated with the Symplicity FlexTM catheter, and 18 were treated with the Symplicity SpyralTM catheter. Baseline office systolic BP was 168.2 ± 19.8 mmHg and diastolic BP was 89.0 ± 14.3 mmHg. Office BP reductions following RDN were sustained throughout the follow-up periods of up to 3 years in the Symplicity FlexTM group and 2 years in the Symplicity SpyralTM group. In the Symplicity FlexTM group, the office systolic BP reductions were 14.9 ± 14.7 mmHg and 29.7 ± 25.9 mmHg at 3 months and 3 years, respectively (both p < 0.05 from baseline). In the Symplicity SpyralTM group, the office systolic BP reductions were 21.2 ± 28.7 mmHg and 42.4 ± 10.7 mmHg at 3 months and 2 years, respectively (both p < 0.05 from baseline). There were no significant changes in heart rate or antihypertensive medication classes. Three protocol-defined adverse events occurred in 2 patients, including new-onset end-stage renal disease, stroke, and hospitalization for new-onset heart failure. CONCLUSIONS: Given the susceptibility of Asian populations to hypertension, RDN, as a safe antihypertensive procedure with long-lasting BP-lowering effects, could reliably serve as an alternative or complementary BP-lowering strategy for patients with uncontrolled hypertension in Taiwan and other Asian countries.
Authors: Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri Journal: Lancet Date: 2018-05-23 Impact factor: 79.321
Authors: Michael Böhm; Felix Mahfoud; Christian Ukena; Uta C Hoppe; Krzysztof Narkiewicz; Manuela Negoita; Luis Ruilope; Markus P Schlaich; Roland E Schmieder; Robert Whitbourn; Bryan Williams; Uwe Zeymer; Andreas Zirlik; Giuseppe Mancia Journal: Hypertension Date: 2015-02-17 Impact factor: 10.190
Authors: Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler Journal: Lancet Date: 2013-11-07 Impact factor: 79.321
Authors: Michel Azizi; Helena Pereira; Idir Hamdidouche; Philippe Gosse; Matthieu Monge; Guillaume Bobrie; Pascal Delsart; Claire Mounier-Véhier; Pierre-Yves Courand; Pierre Lantelme; Thierry Denolle; Caroline Dourmap-Collas; Xavier Girerd; Jean Michel Halimi; Faiez Zannad; Olivier Ormezzano; Bernard Vaïsse; Daniel Herpin; Jean Ribstein; Bernard Chamontin; Jean-Jacques Mourad; Emile Ferrari; Pierre-François Plouin; Vincent Jullien; Marc Sapoval; Gilles Chatellier Journal: Circulation Date: 2016-08-30 Impact factor: 29.690
Authors: Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm Journal: Lancet Date: 2017-08-28 Impact factor: 79.321
Authors: Michael Böhm; Felix Mahfoud; Christian Ukena; Axel Bauer; Eckart Fleck; Uta C Hoppe; Ulrich Kintscher; Krzysztof Narkiewicz; Manuela Negoita; Luis Ruilope; L Christian Rump; Markus Schlaich; Roland Schmieder; Horst Sievert; Joachim Weil; Bryan Williams; Uwe Zeymer; Giuseppe Mancia Journal: EuroIntervention Date: 2013-08-22 Impact factor: 6.534